Practice Updates: Counseling Adolescents About Contraception, Opioid Use and Opioid Use Disorder in Pregnancy

Stay up to date with ACOG's authoritative clinical guidance and helpful patient education materials. The following provides Practice Updates for July and August 2017. 


Featured Committee Opinion: Counseling Adolescents About Contraception

A Committee Opinion from ACOG emphasizes the importance of beginning the conversation between provider and patient about contraception during adolescence. Contraception plays a vital role in women’s health care, including prevention of pregnancy to management of chronic conditions. Most women will use contraception off and on for over 30 years.

ACOG recommends that ob-gyns routinely address their patients’ contraceptive needs, expectations, and concerns and that conversations about contraception begin with the most effective methods. It is also important to be aware of and prepared to address the most common misperceptions about contraceptive methods in a way that is age appropriate and compatible with the patient’s health literacy. The initial encounter and follow-up visits should include continual reassessment of sexual concerns, behavior, relationships, prevention strategies, and testing and treatment for sexually transmitted infections (STIs) per the Centers for Disease Control and Prevention’s (CDC) guidelines.

Committee Opinion 710:Counseling Adolescents About Contraception is available in the August 2017 issue of Obstetrics & Gynecology.


Featured Committee Opinion: Opioid Use and Opioid Use Disorder in Pregnancy

Opioid agonist pharmacotherapy, also known as medication-assisted treatment (MAT), continues to be the recommended therapy for pregnant women with an opioid use disorder. In revised guidance, ACOG also recognizes that medically supervised withdrawal can be considered under the care of a physician experienced in perinatal addiction treatment and with informed consent if a woman does not accept MAT.

It is essential that screening be universal, since screening based only on factors such as poor adherence to prenatal care or prior adverse pregnancy outcome can result in missed cases and may add to stereotyping and stigma. ACOG recommends early universal screening, brief intervention (such as engaging the patient in a short conversation, providing feedback and advice), and referral for treatment of pregnant women with opioid use and opioid use disorder improve maternal and infant outcomes.

Committee Opinion 711: Opioid Use and Opioid Use Disorder in Pregnancy is available in the August 2017 issue of Obstetrics & Gynecology.


Zika Information

ACOG’s Zika webpage

ACOG Zika Practice Advisory

ACOG Zika Toolkit, including patient education video, infographic, and assessment web tool endorsed by CDC

CDC’s Pregnancy and Zika Testing Clinical Algorithm

CDC Zika Virus Website

State Health Department Contact list for ob-gyns (members only) for questions on CDC’s Zika Registry

State Health Department Contact list for ob-gyns (members only) for questions on testing

CDC Zika Pregnancy Hotline for Health Care Providers: Ob-gyns can contact the CDC Zika Pregnancy Hotline at 770-488-7100, or email for any concerns related to clinical management or the US Zika Pregnancy Registry

Office of Population Affairs' Zika Toolkit


New Committee Opinions

See all Committee Opinions


New Practice Bulletins (members only)

See all Practice Bulletins


New Title: Clinical Updates in Women's Health Care (members only)

See all Clinical Updates Titles

New Patient Education Pamphlets (members only)

See all Patient Education Pamphlets

Frequently Asked Questions (FAQs) for Patients

See all Frequently Asked Questions

American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188
Mailing Address: PO Box 96920, Washington, DC 20024-9998